西妥昔单抗
结直肠癌
肿瘤科
癌症
医学
内科学
癌症研究
作者
Elena Élez,Takayuki Yoshino,Lin Shen,Sara Lonardi,Eric Van Cutsem,Cathy Eng,Tae Won Kim,Harpreet Wasan,Jayesh Desai,Fortunato Ciardiello,Rona Yaeger,Tim Maughan,Van K. Morris,Christina Wu,Tiziana Usari,Robert J Laliberte,Samuel S. Dychter,Xiaosong Zhang,Josep Tabernero,Scott Kopetz
标识
DOI:10.1056/nejmoa2501912
摘要
This trial showed significantly longer progression-free survival and overall survival with first-line treatment with EC+mFOLFOX6 than with standard care among patients with BRAF V600E-mutated metastatic colorectal cancer. (Funded by Pfizer and others; BREAKWATER ClinicalTrials.gov number, NCT04607421.).
科研通智能强力驱动
Strongly Powered by AbleSci AI